ETV6-ASCL6 fusion gene screening is recommended for patients with atypical chronic myeloid leukemia, secondary AML, and refractory eosinophilia, in order to judge the prognosis and accumulate more treatment experience. The gene discussed is ETV6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.